Literature DB >> 25092060

Quality-of-life in Charcot-Marie-Tooth disease: the patient's perspective.

Nicholas E Johnson1, Chad R Heatwole2, Nuran Dilek2, Janet Sowden2, Callyn A Kirk3, Denise Shereff4, Michael E Shy5, David N Herrmann2.   

Abstract

This study determines the impact of symptoms associated with Charcot-Marie-Tooth disease on quality-of-life. Charcot-Marie-Tooth patients in the Inherited Neuropathies Consortium Rare Diseases Clinical Research Network Contact Registry were surveyed. The survey inquired about 214 symptoms and 20 themes previously identified as important to Charcot-Marie-Tooth patients through patient interviews. Symptom population impact was calculated as the prevalence multiplied by the relative importance of each symptom identified. Prevalence and symptom impact were analyzed by age, symptom duration, gender, Charcot-Marie-Tooth type, and employment status. 407 participants returned the survey, identifying foot and ankle weakness (99.7%) and impaired balance (98.6%) as the most prevalent themes. Foot and ankle weakness and limitations with mobility were the themes with the highest impact. Both symptom prevalence and impact gradually increased with age and symptom duration. Several themes were more prevalent in women with Charcot-Marie-Tooth, including activity limitations, pain, fatigue, hip-thigh weakness, and gastrointestinal issues. All of the themes, except emotional or body image issues, were more prevalent among unemployed individuals. There were minimal differences in symptom prevalence between Charcot-Marie-Tooth types. There are multiple symptoms that impact Charcot-Marie-Tooth quality-of-life in adults. These symptoms have different levels of importance, are readily recognized by patients, and represent critical areas of Charcot-Marie-Tooth health.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Charcot–Marie–Tooth disease; Patient reported outcomes; Peripheral neuropathy; Quality of life

Mesh:

Year:  2014        PMID: 25092060      PMCID: PMC4253871          DOI: 10.1016/j.nmd.2014.06.433

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  15 in total

1.  Natural history of Charcot-Marie-Tooth 2: 2-year follow-up of muscle strength, walking ability and quality of life.

Authors:  Luca Padua; D Pareyson; I Aprile; T Cavallaro; D A Quattrone; N Rizzuto; G Vita; P Tonali; A Schenone
Journal:  Neurol Sci       Date:  2009-12-17       Impact factor: 3.307

2.  Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project.

Authors:  J E Ware; B Gandek
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

3.  Determinants of reduced health-related quality of life in pediatric inherited neuropathies.

Authors:  J Burns; S Ramchandren; M M Ryan; M Shy; R A Ouvrier
Journal:  Neurology       Date:  2010-08-24       Impact factor: 9.910

4.  Validation of a specific quality of life questionnaire for functional digestive disorders.

Authors:  O Chassany; P Marquis; B Scherrer; N W Read; T Finger; J F Bergmann; B Fraitag; J Geneve; C Caulin
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

5.  The importance of patient-reported outcomes...it's all about the patients.

Authors:  Linda Bren
Journal:  FDA Consum       Date:  2006 Nov-Dec

Review 6.  Patient-reported outcomes to support medical product labeling claims: FDA perspective.

Authors:  Donald L Patrick; Laurie B Burke; John H Powers; Jane A Scott; Edwin P Rock; Sahar Dawisha; Robert O'Neill; Dianne L Kennedy
Journal:  Value Health       Date:  2007 Nov-Dec       Impact factor: 5.725

7.  Correlation between clinical/neurophysiological findings and quality of life in Charcot-Marie-Tooth type 1A.

Authors:  Luca Padua; Michael E Shy; Irene Aprile; Tiziana Cavallaro; Davide Pareyson; Aldo Quattrone; Nicolo Rizzuto; Giuseppe Vita; Pietro Tonali; Angelo Schenone
Journal:  J Peripher Nerv Syst       Date:  2008-03       Impact factor: 3.494

8.  Factors that influence health-related quality of life in Australian adults with Charcot-Marie-Tooth disease.

Authors:  Anthony C Redmond; Joshua Burns; Robert A Ouvrier
Journal:  Neuromuscul Disord       Date:  2008-07-24       Impact factor: 4.296

Review 9.  Diagnosis and new treatments in genetic neuropathies.

Authors:  M M Reilly; M E Shy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-12       Impact factor: 10.154

10.  Fatigue, reduced sleep quality and restless legs syndrome in Charcot-Marie-Tooth disease: a web-based survey.

Authors:  Matthias Boentert; Rainer Dziewas; Anna Heidbreder; Svenja Happe; Ilka Kleffner; Stefan Evers; Peter Young
Journal:  J Neurol       Date:  2009-11-24       Impact factor: 4.849

View more
  14 in total

1.  Targeting Heat Shock Protein 70 to Ameliorate c-Jun Expression and Improve Demyelinating Neuropathy.

Authors:  Xinyue Zhang; Chengyuan Li; Stephen C Fowler; Zheng Zhang; Brian S J Blagg; Rick T Dobrowsky
Journal:  ACS Chem Neurosci       Date:  2017-11-09       Impact factor: 4.418

2.  Management of Stress Urinary Incontinence With Pelvic Floor Muscle Training for a Woman With Charcot-Marie-Tooth Disease: A Case Report.

Authors:  Letícia A Ferreira; Fátima F Fitz; Márcia M Gimenez; Mayanni M P Matias; Maria A T Bortolini; Rodrigo A Castro
Journal:  J Chiropr Med       Date:  2022-06-06

Review 3.  Valuing the "Burden" and Impact of Rare Diseases: A Scoping Review.

Authors:  Julien Delaye; Pasquale Cacciatore; Anna Kole
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

4.  Translation and cross-cultural adaptation of the Charcot-Marie-Tooth disease Pediatric Scale to Brazilian Portuguese and determination of its measurement properties.

Authors:  Karoliny Lisandra Teixeira Cruz; Ana Cristina Resende Camargos; Juliana Cardoso; Cyntia Rogean de Jesus Alves de Baptista; Aline Duprat Ramos; Ana Claudia Mattiello-Sverzut; Joshua Burns; Hércules Ribeiro Leite
Journal:  Braz J Phys Ther       Date:  2020-08-07       Impact factor: 3.377

5.  The Charcot-Marie-Tooth Health Index: Evaluation of a Patient-Reported Outcome.

Authors:  Nicholas E Johnson; Chad Heatwole; Peter Creigh; Michael P McDermott; Nuran Dilek; Man Hung; Jerry Bounsanga; Wan Tang; Michael E Shy; David N Herrmann
Journal:  Ann Neurol       Date:  2018-08-29       Impact factor: 10.422

6.  Patient-Reported Symptoms in Facioscapulohumeral Muscular Dystrophy (PRISM-FSHD).

Authors:  Johanna Hamel; Nicholas Johnson; Rabi Tawil; William B Martens; Nuran Dilek; Michael P McDermott; Chad Heatwole
Journal:  Neurology       Date:  2019-08-13       Impact factor: 9.910

7.  The Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM).

Authors:  Katy Eichinger; Joshua Burns; Kayla Cornett; Chelsea Bacon; Mary Lohse Shepherd; Joan Mountain; Janet Sowden; Rosemary Shy; Michael E Shy; David N Herrmann
Journal:  Neurology       Date:  2018-09-19       Impact factor: 9.910

8.  Cell-Surface and Secreted Isoforms of CSF-1 Exert Opposing Roles in Macrophage-Mediated Neural Damage in Cx32-Deficient Mice.

Authors:  Janos Groh; Ranu Basu; E Richard Stanley; Rudolf Martini
Journal:  J Neurosci       Date:  2016-02-10       Impact factor: 6.167

9.  Endogenous antibodies contribute to macrophage-mediated demyelination in a mouse model for CMT1B.

Authors:  Dennis Klein; Janos Groh; Andreas Weishaupt; Rudolf Martini
Journal:  J Neuroinflammation       Date:  2015-03-12       Impact factor: 8.322

10.  Patient Reported Impact of Symptoms in Spinal Muscular Atrophy (PRISM-SMA).

Authors:  Phillip Mongiovi; Nuran Dilek; Connie Garland; Michael Hunter; John T Kissel; Elizabeth Luebbe; Michael P McDermott; Nicholas Johnson; Chad Heatwole
Journal:  Neurology       Date:  2018-08-24       Impact factor: 11.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.